
Search





In the fourth quarter of 2025, a press release announced the approval of the eighth small interfering RNA (siRNA)-based therapeutic. Redemplo (plozasiran), developed by Arrowhead Pharmaceuticals, is...
From pubmed.ncbi.nlm.nih.govPrion protein (PrP) lowering is effective in animal models of prion disease and is being tested clinically in prion disease patients, but there remains a need for more potent PrP-lowering drug...
From pubmed.ncbi.nlm.nih.gov
Nature Communications - The structure of a type I viral IRES RNA that binds human eIF4G shares a common topology with related RNAs from type II and III IRESs, despite sequence variations, offering...
From nature.comThe anthracycline antibiotic doxorubicin (DOX) is a potent chemotherapy drug, but its use is limited by dose-dependent cardiotoxicity. We previously reported that genetic deletion of p38δ protects...
From pubmed.ncbi.nlm.nih.gov

In the fourth quarter of 2025, a press release announced the approval of the eighth small interfering RNA (siRNA)-based therapeutic. Redemplo (plozasiran), developed by Arrowhead Pharmaceuticals, is...
From pubmed.ncbi.nlm.nih.gov

